Vanda Pharmaceuticals (VNDA) Intangibles (2010 - 2026)

Vanda Pharmaceuticals has reported Intangibles for 17 years, with the latest figure at $115.1 million in Q1 2026.

• Quarterly Intangibles rose 2.45% year-over-year to $115.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.1 million (up 2.45% YoY) and the FY2025 annual result came in at $117.1 million, up 2.62% from the prior year.
• Intangibles eased to $115.1 million in Q1 2026 per VNDA's latest filing, from $117.1 million in the prior quarter.
• Over five years, Intangibles peaked at $121.4 million in Q4 2023 and troughed at $17.4 million in Q3 2023.
• A 5-year average of $75.4 million and a median of $110.6 million in 2025 frame the typical range for Intangibles.
• The sharpest annual moves came in 2023 and 2024: Intangibles fell 8.0% in 2023, then jumped 564.72% in 2024.
• Over 5 years, Intangibles stood at $18.6 million in 2022, then surged by 553.75% to $121.4 million in 2023, then retreated by 5.99% to $114.1 million in 2024, then advanced by 2.62% to $117.1 million in 2025, then declined by 1.7% to $115.1 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $115.1 million, $117.1 million, and $108.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.